TIGIT and glioblastoma: It has been reported that anti-PD-L1 and anti-TIGIT (a novel immune checkpoint inhibitor) combination therapy improved overall survival in GBM patients by increasing effector T cell function and downregulating the number of suppressive Tregs and tumor-infiltrating dendritic cells (43).